Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Immunotherapy in myeloma – where are we?

Keith Stewart • 30 Apr 2020
COMy Virtual 2020
Multiple Myeloma Antibodies bb2121 CAR-T

Keith Stewart, MB, ChB, Mayo Clinic, Rochester, MN, discusses the role of immunotherapy in multiple myeloma (MM), particularly T-cell engaging therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Keith Stewart

The future of myeloma therapy
Brian Walker et al. • 15 Apr 2023
10:38
Day 2 wrap-up: pushing myeloma boundaries
Gareth Morgan et al. • 27 Mar 2022
11:10
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
Faith Davies et al. • 26 Mar 2022
5:02
Drug resistance in multiple myeloma
Keith Stewart • 30 Apr 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals